公司资料
Tiziana Life Sciences 股价、新闻与催化剂
- 股票代码:
- TLSA
- 交易所:
- NASDAQ
- 行业:
- MedTech
- 所在地:
- United Kingdom and trades in the U
股票表现
1.15 USD (+1.32%)
收盘价
最后更新: 2026年8月17日
173M USD
市值
股价为何变动
As of Aug 17, 2026, TLSA closed up 1.32% at $1.15. No new same-company headline was identified in the current news window.
公司概览
业务概览
Tiziana Life Sciences is a biotechnology company focused on immune modulation and respiratory or inflammatory disease applications. Its story centers on using biologic or cellular approaches to influence difficult disease pathways.
所在地与行业分类
Tiziana is headquartered in the United Kingdom and trades in the U.S. market. It sits in small-cap biotechnology.
商业模式特征
The company depends on translational progress, clinical validation, and strategic focus across a narrow pipeline. Investors usually watch early data and whether the platform can sharpen its therapeutic thesis.
生物医药行业定位
Tiziana occupies a niche immune-modulation position within biotech. It is a catalyst-driven small-cap name where scientific proof matters more than commercial scale.
未来催化剂
- Tiziana’s catalysts are foralumab and the neuro / autoimmune programs, with any update that clarifies whether the platform can still progress. The market will want a cleaner clinical path.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。